Several clinical trials have demonstrated the effectiveness of Trop2-targeted therapy in breast cancer. Sacituzumab govitecan (SG) is a Trop2-targeted antibody-drug conjugate (ADC) that has been approved for the treatment of metastatic TNBC and hormone receptor-positive (HR+) and human epidermal...
Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89:4285–9. Article PubMed CAS Google Scholar Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 ...
Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89:4285–9. Article PubMed CAS Google Scholar Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 ...
Breast cancer is the second most common cause of death for women behind lung cancer and the most common cause of cancer deaths for women aged 45–55 years old (CDC.gov 2012). Although there continue to be enormously large numbers of disease incidence, de
HER2 is an established therapeutic target in a large subset of women with breast cancer; a variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1) have been approved for the treatment of HER2-positive breast cancer. HER2 is also overexpressed in ...
Targeted therapies of breast cancer offer a possibility of effective and individualized therapy based on the molecular profile of the tumor. Currently there are three main types of targeted therapeutic drugs for breast cancer, the first category is the monoclonal antibody against the human epidermal gr...
Updates on Targeted Therapy for Triple-Negative Breast Cancer (TNBC) Introduction Based on the American Cancer Society, breast cancer (BC) has emerged as the second leading cause of cancer death in women, and the incidence of BC is increasing annually [1,2]. According to the expression of bi...
Breast cancer is a complex and heterogeneous disease.Targeted therapies for breast cancer are evolving rapidly.Trastuzumab therapy for HER?2-positive metastatic breast cancer was approved by FDA in 1997.Since that day,other targeted therapies,such as lapatinib,a dual human epidermal growth factor recep...
Targeted Therapies for Solid Tumors Maria Vittoria Dieci, Valentina Guarneri, Carlo Alberto Giorgi& Pierfranco Conte Part of the book series:Current Clinical Pathology((CCPATH)) 1178Accesses Abstract Breast cancer is a heterogeneous disease, encompassing at least three different tumor subtypes: the horm...
The U.S. Food and Drug Administration has approved Enhertu (am-trastuzumab-deruxtecan-nxki), an intravenous infusion treatment for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low breast cancer.